Vipergen

Vipergen is a private, revenue-generating service provider in the drug discovery sector, leveraging its innovative second- and third-generation DNA-encoded library (DEL) platforms. Its core technologies—YoctoReactor®, Binder Trap Enrichment (BTE), and Cellular Binder Trap Enrichment (cBTE)—enable screening under physiologically relevant conditions without requiring purified target proteins, expanding the accessible target space. The company operates on a flexible partnership model, from fee-for-service to joint ventures, collaborating with biopharma clients to identify early-stage hits and leads for complex targets.

Proprietary DNA-encoded library (DEL) platforms including YoctoReactor® for high-fidelity library synthesis, Binder Trap Enrichment (BTE) for purified target screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly in living cells under physiological conditions.

Vipergen competes in the DNA-encoded library screening services market against firms like X-Chem (acquired by Revvity), DyNAbind, and the DEL divisions of large contract research organizations (CROs). Its key differentiation is the proprietary cBTE technology for cell-native screening, which is less common among competitors who often rely on purified protein targets.